1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Clinical Review
Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: A review
Article first published online: 25 OCT 2010
DOI: 10.1002/ibd.21488
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Park, K.T. and Bass, D. (2011), Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: A review. Inflamm Bowel Dis, 17: 1603–1609. doi: 10.1002/ibd.21488
Publication History
- Issue published online: 14 JUN 2011
- Article first published online: 25 OCT 2010
- Manuscript Accepted: 14 AUG 2010
- Manuscript Received: 9 AUG 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- healthcare cost;
- inflammatory bowel disease;
- cost effectiveness analysis
Abstract
The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD costs have shifted from inpatient to outpatient care since the introduction of biologic therapies as the standard of care. Gastroenterologists need to be aware of the national cost burden of IBD and clinical practices that optimize cost-efficiency. This investigation offers a systematic review of the economics of IBD and evidence-based strategies for cost-effective management. (Inflamm Bowel Dis 2010;)